Serametrix, Ludwig Institute to Develop Cancer Rx-Response Test | GenomeWeb

NEW YORK (GenomeWeb News) — Personalized medicine company Serametrix announced today a partnership with the Ludwig Institute for Cancer Research to develop serum-based diagnostics to predict and monitor treatment response in cancer patients.

As part of the agreement, LICR has licensed to Serametrix tumor antigen patents surrounding the use of the antigen NY-ESO-1 as a predictor of drug response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.